IGC Pharma, Inc. - IGC STOCK NEWS

Welcome to our dedicated page for IGC Pharma news (Ticker: IGC), a resource for investors and traders seeking the latest updates and insights on IGC Pharma stock.

IGC Pharma, Inc. (IGC) is at the forefront of developing innovative phytocannabinoid-based therapies aimed at treating a wide range of therapeutic indications. The company is involved in cutting-edge research to develop treatments for conditions such as neuropathic and cancer pain, epilepsy, and chronic neurological and oncological diagnoses, which can be life-altering or life-threatening. The mission of IGC Pharma is to alleviate pain, PTSD, seizures, cachexia, and other severe conditions through advanced cannabinoid-based formulations.

One of the primary focuses of IGC Pharma is to combat Alzheimer's disease. The company has developed two investigational drug assets, IGC-AD1 and TGR-63, that have shown potential in reducing key hallmarks of Alzheimer's, such as plaques and tangles, in cell line studies. IGC-AD1, a low-dose tetrahydrocannabinol-based formulation, is currently undergoing a Phase 2 clinical trial involving 146 participants to evaluate its efficacy in treating agitation in dementia due to Alzheimer's.

Beyond Alzheimer's treatment, IGC Pharma also addresses women's health through its wellness brand Holief, which provides relief for premenstrual syndrome and menstrual cramps. This diversified approach highlights the company’s commitment to improving quality of life across various patient demographics.

IGC Pharma's innovative research and development are complemented by strategic partnerships and a robust product portfolio, which collectively enhance its market presence and potential for growth.

11/13/2023 08:00 AM

News

IGC Pharma Reports Second Quarter Fiscal 2024 Results

Rhea-AI Summary

IGC Pharma, Inc. (NYSE American: IGC) reports 44% revenue growth in Q2 FY2024, signaling progress in Phase 2 Trial for Alzheimer’s treatment. The company is focused on expanding its IP portfolio targeting Alzheimer’s, addressing agitation in dementia.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

3.33%

Tags

10/19/2023 03:30 PM

News

IGC Pharma Granted European Patent for Groundbreaking Cannabinoid-Based Pain Topical Relief Therapy

Rhea-AI Summary

IGC Pharma, Inc. has been granted a European patent for its innovative cannabinoid composition and method for treating pain. The company aims to revolutionize pain relief by offering a cream or gel infused with cannabinoids that provides effective pain relief without psychotropic or adverse side effects.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

08/21/2023 02:30 PM

News

IGC Announces Results of its 2023 Annual Stockholders Meeting

Rhea-AI Summary

IGC Pharma, Inc. announces approval of proposals at Annual Meeting

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

08/14/2023 08:30 AM

News

IGC Pharma Reports First Quarter Results; Company Continues to Make Significant Progress Advancing Its Lead Alzheimer’s Candidate Through Phase 2 Clinical Trials

Rhea-AI Summary

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-2.78%

Tags

08/02/2023 08:30 AM

News

IGC Pharma Expands Phase 2 Trial of IGC-AD1 to Include the University of Puerto Rico

Rhea-AI Summary

IGC Pharma, Inc (NYSE American: IGC) announced the addition of an important trial site at the University of Puerto Rico network as an expansion of the ongoing Phase 2 clinical trial investigating lead drug asset, IGC-AD1, as a treatment for lowering agitation in patients with Alzheimer’s disease. The trial will enroll 146 patients with the goal of evaluating the efficacy of IGC-AD1 in helping patients with Alzheimer’s dementia reduce neuropsychiatric symptoms such as agitation. The addition of the Puerto Rico site aims to increase population diversity and promote the inclusion of underrepresented populations.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

07/18/2023 05:22 AM

News

IGC Pharma, Inc. Presenting 6 Posters on the Positive Impact of IGC-AD1 on Neuropsychiatric Symptoms in Dementia at the 2023 Alzheimer’s Association International Conference

Rhea-AI Summary

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

07/12/2023 08:44 AM

News

IGC Reports Financial Results for Fiscal Year Ended March 31, 2023

Rhea-AI Summary

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-5%

Tags

07/07/2023 09:15 AM

News

IGC Pharma Secures $12 Million Line of Credit from O-Bank Strengthening Efforts in Alzheimer's Research

Rhea-AI Summary

IGC Pharma secures $12 million revolving line of credit for Alzheimer's research. The line of credit will support IGC's working capital needs, with the ability to draw up to $1 million within 30 days. Bradbury Asset Management collateralized cash assets in support of the line of credit. IGC-AD1, a potential treatment for agitation in dementia due to Alzheimer's, is currently in Phase 2 clinical trials.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

24.24%

Tags

07/06/2023 07:46 AM

News

IGC Pharma Announces a $3 Million Private Placement of its Common Stock

Rhea-AI Summary

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-2.94%

Tags

06/06/2023 09:20 AM

News

IGC Pharma Receives Notice of Allowance for Patent on Seizures

Rhea-AI Summary

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-3.13%

Tags

FAQ

What is the current stock price of IGC Pharma (IGC)?

The current stock price of IGC Pharma (IGC) is $0.3541 as of September 27, 2024.

What is the market cap of IGC Pharma (IGC)?

The market cap of IGC Pharma (IGC) is approximately 22.9M.

What is the main focus of IGC Pharma, Inc.?

IGC Pharma focuses on developing phytocannabinoid-based therapies for various severe conditions, including neuropathic pain, Alzheimer's disease, and chronic neurological diagnoses.

What are IGC Pharma's key investigational drug assets for Alzheimer's?

IGC Pharma's key investigational drugs for Alzheimer's are IGC-AD1 and TGR-63, which have shown promise in reducing Alzheimer's biomarkers in cell line studies.

What is the status of IGC-AD1?

IGC-AD1 is in a Phase 2 clinical trial with 146 participants, aimed at evaluating its efficacy in treating agitation in dementia due to Alzheimer's.

Does IGC Pharma have products targeting women's health?

Yes, IGC Pharma markets the Holief brand, which targets women experiencing premenstrual syndrome and menstrual cramps.

What conditions does IGC Pharma aim to treat with its therapies?

IGC Pharma aims to treat conditions such as pain, PTSD, seizures, cachexia, Alzheimer's disease, and other chronic and terminal neurological and oncological diagnoses.

How does IGC Pharma contribute to Alzheimer's research?

IGC Pharma contributes through its development of IGC-AD1 and TGR-63, which target key hallmarks of Alzheimer's disease, such as plaques and tangles.

What is the mission of IGC Pharma?

The mission of IGC Pharma is to treat severe and life-altering conditions using advanced cannabinoid-based formulations.

What is the significance of IGC's research on neuropathic and cancer pain?

IGC's research aims to provide effective phytocannabinoid-based therapies for managing neuropathic and cancer pain, improving patient quality of life.

Does IGC Pharma have any products in the wellness market?

Yes, IGC Pharma's wellness brand Holief targets women suffering from premenstrual syndrome and menstrual cramps.

What makes IGC Pharma unique in the biotech industry?

IGC Pharma's unique approach lies in its focus on phytocannabinoid-based therapies, targeting a wide range of severe conditions, and its diverse product portfolio including wellness products.